NEW YORK, Sept. 5 (GenomeWeb News) - Intradigm announced today that it had developed siRNA capable of achieving 90 percent inhibition of the SARS virus in cell-based studies.
The Rockville, Md.-based RNAi company collaborated with Qiagen to design the siRNA, which targeted specific genes throughout the SARS genome. Qiagen synthesized the siRNA, and the product was tested in laboratories in Hong Kong and Guangzhou, China using non-human primate cells exposed to the SARS virus. Hong Kong-based Top Biotech sponsored the effort along with the provincial government of Guangdong province, China. Scientists from GuangzhouMedicalUniversity and Zhongshan University of Guangzhou, as well as Hong KongUniversity also worked on the project.
Intradigm has already established a collaboration with scientists from the National Institute of Allergy and Infectious Diseases in the US, and from institutions in Hong Kong and Guangzhou to develop siRNA-based anti-SARS therapies.